GSK shares up on US priority review for Gepotidacin
FDA accepts application for gepotidacin Positive phase-three trials GAK to receive $370m settlement Pharmaceutical firm GSK (GSK) said the US FDA (Food and Drug Administration) has accepted an application to review gepotidacin, its...
11 August 2025